Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:BLTE NASDAQ:IBRX NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$20.57+4.1%$16.65$8.03▼$21.30$2.37B2.062.02 million shs1.92 million shsBLTEBelite Bio$77.40-0.9%$68.35$49.00▼$86.53$2.49B-1.4662,212 shs126,539 shsIBRXImmunityBio$2.50-1.2%$2.49$1.83▼$7.48$2.39B0.2710.92 million shs9.58 million shsSVRASavara$3.43-0.9%$3.25$1.89▼$4.30$598.02M0.461.15 million shs886,388 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+4.10%+9.12%+19.94%+44.66%+110.11%BLTEBelite Bio-0.90%+4.59%+17.74%+20.64%+52.06%IBRXImmunityBio-1.19%+1.63%+4.17%-10.39%-28.37%SVRASavara-0.87%-3.92%-7.80%+44.73%-8.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$20.57+4.1%$16.65$8.03▼$21.30$2.37B2.062.02 million shs1.92 million shsBLTEBelite Bio$77.40-0.9%$68.35$49.00▼$86.53$2.49B-1.4662,212 shs126,539 shsIBRXImmunityBio$2.50-1.2%$2.49$1.83▼$7.48$2.39B0.2710.92 million shs9.58 million shsSVRASavara$3.43-0.9%$3.25$1.89▼$4.30$598.02M0.461.15 million shs886,388 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+4.10%+9.12%+19.94%+44.66%+110.11%BLTEBelite Bio-0.90%+4.59%+17.74%+20.64%+52.06%IBRXImmunityBio-1.19%+1.63%+4.17%-10.39%-28.37%SVRASavara-0.87%-3.92%-7.80%+44.73%-8.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.63Moderate Buy$19.80-3.74% DownsideBLTEBelite Bio 2.50Moderate Buy$96.0024.03% UpsideIBRXImmunityBio 2.83Moderate Buy$10.75330.00% UpsideSVRASavara 2.57Moderate Buy$7.50118.66% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, BLTE, IBRX, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ARQTArcutis BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BLTEBelite BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IBRXImmunityBioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/16/2025BLTEBelite BioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $98.009/10/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.009/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M12.55N/AN/A$1.35 per share15.24BLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/AIBRXImmunityBio$14.74M160.32N/AN/A($0.57) per share-4.39SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$0.75N/AN/AN/A-35.40%-62.62%-25.16%10/28/2025 (Estimated)BLTEBelite Bio-$36.14M-$1.55N/AN/AN/AN/A-34.90%-33.56%11/11/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest SVRA, BLTE, IBRX, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/28/2025Q3 2025ARQTArcutis Biotherapeutics-$0.09N/AN/AN/A$86.69 millionN/A8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/11/2025Q2 2025BLTEBelite Bio-$0.47-$0.50-$0.03-$0.50N/AN/A8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 million8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.773.203.04BLTEBelite BioN/A23.1523.15IBRXImmunityBioN/A4.113.98SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABLTEBelite Bio0.53%IBRXImmunityBio8.58%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BLTEBelite Bio13.29%IBRXImmunityBio76.79%SVRASavara5.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.90 million108.63 millionOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableIBRXImmunityBio590945.26 million219.39 millionOptionableSVRASavara20172.84 million163.97 millionOptionableSVRA, BLTE, IBRX, and ARQT HeadlinesRecent News About These CompaniesClass Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline5 hours ago | theglobeandmail.comSavara Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRAOctober 7 at 5:58 PM | theglobeandmail.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud LawsuitOctober 7 at 4:17 PM | prnewswire.comSavara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 7 at 3:57 PM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 7 at 7:42 AM | prnewswire.comSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 7 at 7:40 AM | prnewswire.comSavara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds Savara Inc. Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitOctober 6 at 6:00 PM | globenewswire.comLost Money on Savara Inc. (SVRA)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyOctober 6 at 4:48 PM | globenewswire.comDeadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitOctober 6 at 4:45 PM | globenewswire.comSAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the November 7th Deadline in The Savara Class Action LawsuitOctober 6 at 2:25 PM | globenewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRAOctober 6 at 8:45 AM | prnewswire.comSVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraOctober 5 at 11:10 PM | globenewswire.comSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 5 at 2:31 PM | markets.businessinsider.comSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 3, 2025 | globenewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraOctober 3, 2025 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRAOctober 3, 2025 | prnewswire.comSavara Inc. (NASDAQ:SVRA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 3, 2025 | marketbeat.comSavara present results from Phase 3 IMPALA-2 Molgramostim studyOctober 2, 2025 | msn.comClass Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact Levi & KorsinskyOctober 2, 2025 | theglobeandmail.comSavara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune ...October 2, 2025 | caledonianrecord.comCSVRA NOTICE: Savara Inc. Investors Urged to Contact Kirby McInerney LLP About Securities Fraud LawsuitOctober 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025SVRA, BLTE, IBRX, and ARQT Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$20.57 +0.81 (+4.10%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$20.75 +0.18 (+0.88%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Belite Bio NASDAQ:BLTE$77.40 -0.70 (-0.90%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$77.70 +0.30 (+0.39%) As of 10/7/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.ImmunityBio NASDAQ:IBRX$2.50 -0.03 (-1.19%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$2.52 +0.02 (+1.00%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Savara NASDAQ:SVRA$3.43 -0.03 (-0.87%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$3.42 -0.02 (-0.44%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
